FDA Extends Review of Reproxalap for Dry Eye Disease to March 16 Amid Clinical Study Requests
The FDA extended its review of Aldeyra’s reproxalap for dry eye disease to March 16, 2026, after requesting a clinical study report.
Read More
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
DAILYZ HEALTH NEWS
ALL ABOUT DAILYZ HEALTH NEWS
Aldeyra Pharmaceuticals